Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma (vol 40, pg 477, 2010)

被引：0
|
作者：
Yasuda, E.
Kumada, T.
Toyoda, H.
Kaneoka, Y.
Maeda, A.
Okuda, S.
Yoshimi, N.
Kozawa, O.
机构：
来源：
HEPATOLOGY RESEARCH | 2011年 / 41卷 / 01期
关键词：
D O I：
10.1111/j.1872-034X.2010.00767.x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：101 / 101
页数：1
相关论文
共 9 条
  • [1] Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma
    Yasuda, Eisuke
    Kumada, Takashi
    Toyoda, Hidenori
    Kaneoka, Yuji
    Maeda, Atsuyuki
    Okuda, Seiji
    Yoshimi, Naoki
    Kozawa, Osamu
    HEPATOLOGY RESEARCH, 2010, 40 (05) : 477 - 485
  • [2] An Assessment of the Heterogeneous Expression of Glypican-3 (GPC3) in Hepatocellular Carcinoma (HCC) in the Era of GPC3 as a Biomarker
    Cox, Brian
    Waters, Kevin
    Dhall, Deepti
    Larson, Brent
    Guindi, Maha
    LABORATORY INVESTIGATION, 2019, 99
  • [3] An Assessment of the Heterogeneous Expression of Glypican-3 (GPC3) in Hepatocellular Carcinoma (HCC) in the Era of GPC3 as a Biomarker
    Cox, Brian
    Waters, Kevin
    Dhall, Deepti
    Larson, Brent
    Guindi, Maha
    MODERN PATHOLOGY, 2019, 32
  • [4] A correlation between Glypican-3 (GPC3) expression and the grading system in hepatocellular carcinoma
    Herlea, V.
    Procop, A.
    Pechianu, C.
    Mihai, M.
    Mustafa, E. Stoica
    Hortopan, M.
    Iorgescu, A.
    Andreoiu, O. -M.
    Varban, S.
    Popescu, I.
    VIRCHOWS ARCHIV, 2017, 471 : S134 - S134
  • [5] Immunological efficacy of glypican-3 (GPC3) peptide vaccine in patients with advanced hepatocellular carcinoma
    Tsuchiya, Nobuhiro
    Yoshikawa, Toshiaki
    Fujinami, Norihiro
    Saito, Keigo
    Shimomura, Manami
    Suzuki, Toshihiro
    Nosaka, Kazuto
    Shimizu, Hiroyasu
    Akazawa, Yu
    Charneau, Jimmy
    Sawada, Yu
    Endo, Itaru
    Nakatsura, Tetsuya
    CANCER SCIENCE, 2018, 109 : 276 - 276
  • [6] Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significance
    Yu, X.
    Li, Y.
    Chen, S. W.
    Shi, Y.
    Xu, F.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03) : 10185 - 10192
  • [7] Glypican-3 (GPC3) and NKp46 directed FLEX-NK engager antibody (CYT-303) recruits natural killer (NK) cells to tumors in a preclinical hepatocellular carcinoma (HCC) mouse model
    Arulanandam, A.
    Potu, H.
    Khairnar, V.
    Zou, D.
    Triggiano, M.
    Dilmac, N.
    Lin, L.
    Chang, H-M.
    Welch, A.
    Mandelboim, O.
    Ilan, Y.
    Teper, D.
    Frankel, S.
    Kadouche, J.
    Li, W.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S889 - S889
  • [8] Allogeneic Vδ1 gamma delta T cells engineered with glypican-3 (GPC3)-specific CAR expressing soluble IL-15 have enhanced antitumor efficacy against hepatocellular carcinoma in preclinical models.
    Makkouk, Amani
    Yang, Xue
    Barca, Taylor
    Lucas, Anthony
    Turkoz, Mustafa
    Nishimoto, Kevin
    Brodey, Mary
    Tabrizizad, Maryam
    Bai, Lu
    Nguyen, Kevin
    Salum, Michael
    An, Zili
    Abbot, Stewart
    Satpayev, Daulet
    Herrman, Marissa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Preclinical activity of glypican-3 (GPC3) and NKp46 directed FLEX-NKT engager antibody (CYT-303) in combination with iPSC derived natural killer cells (iNKs) or peripheral blood (PB) NK cells in hepatocellular carcinoma (HCC)
    Arulanandam, Antonio
    Lin, Liang
    Chang, Hao-Ming
    Potu, Harish
    Khairnar, Vishal
    Zou, David
    Triggiano, Melissa
    Dilmac, Nejmi
    Yang, Yinan
    Kahlon, Shira
    Frankel, Stanley
    Kadouche, Jean
    Teper, Daniel
    Mandelboim, Ofer
    Hershkovitz, Yoav
    Ilan, Yaron
    Li, Wei
    CLINICAL CANCER RESEARCH, 2022, 28 (17)
1